Perimeter Medical Imaging AI, Inc. (TSXV:PINK)
Canada · Delayed Price · Currency is CAD | Market Cap | 55.24M +106.7% |
| Revenue (ttm) | 2.98M +49.4% |
| Net Income | -16.16M |
| EPS | -0.18 |
| Shares Out | 153.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 832,340 |
| Open | 0.3550 |
| Previous Close | 0.3600 |
| Day's Range | 0.2900 - 0.3550 |
| 52-Week Range | 0.1700 - 0.7200 |
| Beta | 1.11 |
| Analysts | Buy |
| Price Target | 1.61 (+445.76%) |
| Earnings Date | Aug 20, 2026 |
About TSXV:PINK
Perimeter Medical Imaging AI, Inc., a medical technology company, provides advanced imaging solutions to address unmet medical needs. The company offers the Perimeter S-Series optical coherence tomography (OCT) imaging system, which delivers cross-sectional, real-time margin visualization of excised tissue specimens in the operating room. It also provides Claire OCT, with ImgAssist artificial intelligence for patients undergoing breast conservation surgery. In addition, the company provides a proprietary image library and consumable specimen co... [Read more]
Financial Performance
In 2025, TSXV:PINK's revenue was $2.30 million, an increase of 132.47% compared to the previous year's $990,969. Losses were -$12.92 million, -3.57% less than in 2024.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for PINK stock is "Buy." The 12-month stock price target is $1.61, which is an increase of 445.76% from the latest price.
News
Perimeter Medical Imaging AI Earnings Call Transcript: Q2 2026
Q2 2026 saw strong recurring revenue growth (31% sequentially), reduced operating expenses, and the first commercial deployments of the Claire AI-enabled device. With a robust sales pipeline and expanding team, rapid revenue growth is anticipated as Claire adoption accelerates.
Perimeter Medical Imaging AI Earnings release: Q2 2026
Perimeter Medical Imaging AI released its Q2 2026 earnings on August 20, 2026, summarizing the period's financial results.
Perimeter Announces Preliminary Second Quarter 2026 Financial Results
Results characterized by continued strong commercial momentum and improved operating performance Conference call/webcast today at 5:00 pm ET TORONTO and DALLAS, Aug. 20, 2026 /PRNewswire/ -- Perimeter...
Perimeter Schedules Second Quarter 2026 Financial Results Conference Call for August 20th
TORONTO and DALLAS, Aug. 13, 2026 /PRNewswire/ -- Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announce...
Intermountain Health Brings Perimeter's Claire™ to the Operating Room, a Landmark in Breast Cancer Surgery Using AI
Health system is first to commercially deploy Claire, the only FDA-approved, AI-enabled imaging device for margin assessment during breast-conserving surgery in the U.S. Claire is designed to enhance ...
Perimeter Medical Imaging AI initiated with a Buy at Brookline
Brookline initiated coverage of Perimeter Medical Imaging AI (PYNKF) with a Buy rating and C$1.54 price target
Perimeter Medical Imaging AI Transcript: Planet MicroCap Las Vegas 2026
A novel AI-enabled imaging device for breast cancer surgery has achieved FDA approval and demonstrated clinical success in reducing reoperations, with a strong recurring revenue model and significant competitive moats. The company is focused on targeted U.S. expansion, ongoing AI improvements, and plans to uplist to NASDAQ within two years.
Perimeter Medical Imaging AI Slides: Investor presentation
Perimeter Medical Imaging AI has posted slides in relation to its latest quarterly earnings report, which was published on June 17, 2026.
Perimeter Medical Imaging AI to Participate in the Planet MicroCap Showcase in Las Vegas
TORONTO and DALLAS, June 15, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is please...
Perimeter Selected for INOVAIT Pilot Fund to Advance AI for Breast Cancer Surgery
Canadian government-backed contribution supports next-generation AI development for Claire™, Perimeter's flagship intraoperative imaging platform TORONTO, June 9, 2026 /PRNewswire/ - Perimeter Medical...
Perimeter Medical Imaging AI Earnings Call Transcript: Q1 2026
Q1 2026 saw 14% recurring revenue growth and a 31% reduction in net loss, driven by S-Series OCT, while FDA approval of the Claire OCT plus AI device positions the company for rapid growth. Over $9.5M in new capital supports a 12-month runway.
Perimeter Medical Imaging AI Registration statement: Q1 2026
Perimeter Medical Imaging AI filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
Perimeter Medical Imaging AI Registration statement: Q1 2026
Perimeter Medical Imaging AI filed a registration statement on May 28, 2026, providing details about a securities offering with the SEC.
Perimeter Medical Imaging AI Earnings release: Q1 2026
Perimeter Medical Imaging AI released its Q1 2026 earnings on May 28, 2026, summarizing the period's financial results.
Perimeter Announces First Quarter 2026 Financial Results
Conference call/webcast today at 5:00 pm ET TORONTO and DALLAS, May 28, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-...
Perimeter Schedules First Quarter 2026 Financial Results Conference Call for May 28th
TORONTO and DALLAS, May 21, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, announced ...
Perimeter Showcases Claire™ for Intraoperative Breast Cancer Margin Assessment at ASBrS 2026
New advanced imaging and AI capabilities revealed for first time ahead of commercial launch TORONTO and DALLAS, April 29, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PY...
Perimeter Medical Imaging AI Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
A newly FDA-approved AI imaging device for breast cancer surgery is entering commercialization, targeting a large U.S. and global market with a high-margin, recurring revenue model. Expansion plans include new cancer types, international growth, and a NASDAQ listing, supported by ongoing fundraising.
Perimeter Medical Imaging AI to Participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference
TORONTO and DALLAS, April 14, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleas...
Perimeter Medical Imaging AI Earnings Call Transcript: Q4 2025
Record Q4 2025 revenue and reduced losses reflect strong S-Series adoption and cost controls. FDA PMA approval for Claire OCT sets the stage for commercial launch and broader market penetration in 2026, with new recurring revenue streams anticipated.
Perimeter Medical Imaging AI Earnings release: Q4 2025
Perimeter Medical Imaging AI released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
Perimeter Medical Imaging AI Registration statement: Q4 2025
Perimeter Medical Imaging AI filed a registration statement on March 31, 2026, providing details about a securities offering with the SEC.
Perimeter Medical Imaging AI Registration statement: Q4 2025
Perimeter Medical Imaging AI filed a registration statement on March 31, 2026, providing details about a securities offering with the SEC.
Perimeter Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results Marked by Record Revenues and Improved Operating Performance
Conference Call/Webcast Today at 5:00 pm ET TORONTO and DALLAS, March 31, 2026 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercia...
Perimeter Medical Imaging AI Slides: Investor presentation
Perimeter Medical Imaging AI has posted slides in relation to its latest quarterly earnings report, which was published on March 25, 2026.